HDSA 2025: Speakers spotlight Huntington's clinical trials
Speakers at the 2025 HDSA convention highlighted clinical trials testing several treatments aimed at mutant huntingtin.| Huntington's Disease News
uniQure’s experimental gene therapy AMT-130 safely and effectively slows the progression of Huntington’s disease, according to top-line, three-year data from two Phase 1/2 clinical trials. At 36 months, the use […] The post Gene therapy AMT-130 slows Huntington’s progression by 75% appeared first on Huntington's Disease News.| Huntington's Disease News – The Web's Daily Resource for Huntington's Disea...
Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements as a method to track Huntington’s disease activity in clinical trials. The […] The post Eye movement could help track Huntington’s disease activity appeared first on Huntington's Disease News.| Huntington's Disease News – The Web's Daily Resource for Huntington's Disea...
Speakers at the 2025 HDSA convention highlighted clinical trials testing several treatments aimed at mutant huntingtin.| Huntington's Disease News
